STOCK TITAN
  1. Home
  2. Sec-filings
  3. CORT
  4. [Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity

Corcept (NASDAQ: CORT) CBO reports equity awards and tax-share withholding

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Corcept Therapeutics’ Chief Business Officer Gary Charles Robb reported routine equity compensation and related tax withholding in common stock. On June 1, 2026, he acquired 776 shares under a purchase plan established within the 2024 Incentive Award Plan, with the price based on the closing price that day. The filing also notes restricted stock awards that vest after one year if specific service or ownership conditions are met. On June 2, 2026, 358 shares were withheld by the company at $70.44 per share to satisfy tax obligations tied to vesting restricted stock units, leaving him with 25,681 directly held shares. Additional common stock is held indirectly through a revocable trust and custodial accounts for his children.

Positive

  • None.

Negative

  • None.
Insider Robb Gary Charles
Role Chief Business Officer
Type Security Shares Price Value
Exercise Price or Tax Liability Common Stock 358 $70.44 $25K
Grant/Award Common Stock 776 $70.44 $55K
Grant/Award Common Stock 776 $0.00 $0.00
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 25,681 shares (Direct); Common Stock — 25,142 shares (Indirect, Custodial Account for Child); Common Stock — 49,716 shares (Indirect, Gary Charles Robb TTE Robb Revocable Trust)
Footnotes (10)
  1. F1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026.
  2. F2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
  3. F3. Includes 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, and 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  4. F4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
  5. F5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
  6. F6. The closing price on June 1, 2026 was used to calculate the withholding obligation.
  7. F7. Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, and 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  8. F8. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
  9. F9. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
  10. F10. These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.
Equity award shares 776 shares Grant/award acquisition of common stock on June 1, 2026
Tax withholding shares 358 shares Shares withheld to satisfy tax obligations on June 2, 2026
Tax withholding price $70.44 per share Price used to calculate withholding obligation on June 1–2, 2026
Direct holdings post-transaction 25,681 shares Directly held Corcept common stock after June 2, 2026 transaction
Trust holdings 49,716 shares Common stock held indirectly via Robb Revocable Trust
Custodial account holdings 12,571 shares Common stock held indirectly in a custodial account for a child
restricted stock awards financial
"Includes 997 shares underlying unvested restricted stock awards granted to the Reporting Person..."
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
restricted stock units financial
"tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Purchase Plan financial
"purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan..."
2024 Incentive Award Plan financial
"purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026."
tax withholding obligations financial
"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units."
Uniform Transfers to Minors Act financial
"custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transactions did CORT executive Gary Charles Robb report in this Form 4?
Gary Charles Robb reported routine equity compensation and tax withholding. He acquired 776 Corcept Therapeutics common shares under a purchase plan and had 358 shares withheld by the company to cover tax obligations associated with vesting restricted stock units.

How many Corcept Therapeutics (CORT) shares does Gary Charles Robb hold directly after these transactions?
After the reported transactions, Gary Charles Robb directly holds 25,681 Corcept Therapeutics common shares. This reflects equity awards and tax withholding and does not include additional indirect holdings through a revocable trust and custodial accounts for his children.

What is the nature of the 776 Corcept Therapeutics shares acquired by Gary Charles Robb?
The 776 shares were acquired as part of a grant or award under a purchase plan established within Corcept’s 2024 Incentive Award Plan. The purchase price was determined using the common stock’s closing price on June 1, 2026, according to the filing footnotes.

Why were 358 CORT shares disposed of in Gary Charles Robb’s Form 4 filing?
The 358 shares were withheld by Corcept Therapeutics to satisfy tax withholding obligations when restricted stock units vested. This tax-withholding disposition is coded as an F transaction and is not an open-market sale, but a mechanism to pay required taxes in shares.

What indirect Corcept Therapeutics (CORT) holdings are reported for Gary Charles Robb?
The filing shows indirect holdings through the Gary Charles Robb TTE Robb Revocable Trust and custodial accounts for his children under the Uniform Transfers to Minors Act. These positions are reported as indirect ownership separate from his directly held common stock.

How do Gary Charles Robb’s restricted stock awards in CORT vest over time?
Certain restricted stock awards vest 100% on the one-year anniversary of their grant date. Vesting requires that Gary Charles Robb satisfy service requirements or, for some awards tied to purchase plan shares, remain the beneficial owner of those shares through the one-year anniversary.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Robb Gary Charles
(Last)(First)(Middle)
C/O CORCEPT THERAPEUTICS INCORPORATED
101 REDWOOD SHORES PARKWAY
(Street)
REDWOOD CITY CALIFORNIA 94065
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Business Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/01/2026A776(1)A$70.44(2)25,263(3)D
Common Stock06/01/2026A776(4)A$0.0026,039(3)D
Common Stock06/02/2026F(5)358D$70.44(6)25,681(7)D
Common Stock12,571ICustodial Account for Child(8)
Common Stock12,571ICustodial Account for Child(9)
Common Stock49,716IGary Charles Robb TTE Robb Revocable Trust(10)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026.
2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
3. Includes 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, and 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
6. The closing price on June 1, 2026 was used to calculate the withholding obligation.
7. Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, and 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
8. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
9. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
10. These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.
Remarks:
The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for Gary Charles Robb.06/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR